PR Newswire·Nov 12, 2026, 8:31 AM ET

MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial

MetaVia Inc. announced additional positive Phase 1 Part 3B data for its drug candidate DA-1726 in otherwise healthy adults with obesity.
DA-1726 treatment resulted in a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks (p<0.001).
Participants in the DA-1726 group had mean baseline uric acid levels within the normal range, making the reduction notable despite no hyperuricemia at entry.
All five DA-1726-treated participants with baseline liver steatosis achieved normalization of liver fat (MRI-PDFF below 5%) by Day 109.
Previous interim results confirmed a 68.1% placebo-adjusted reduction in liver fat, 13.5% placebo-adjusted weight loss, and a 0.44 absolute percentage-point reduction in HbA1c.
DA-1726 is a novel oxyntomodulin analog acting as a dual agonist of GLP-1 and glucagon receptors administered via once-weekly subcutaneous injection.
MetaVia plans to report full data from Part 3A and Part 3B in the first quarter of 2027.
A 48-week, non-biopsy Phase 2 study targeting up to 150 subjects with MetALD and ALD is targeted to begin in the second half of 2027.
The company is also advancing vanoglipel (DA-1241) in combination with resmetirom for Metabolic Dysfunction-Associated Steatohepatitis (MASH).